My PCR
Create Account
Logo PCR

20 May 2026

TAVI

TAVI: head-to-head trials

Session comprising selected EuroPCR 2026 late-breaking trials submissions

Anchorperson: M. Leon
Spokesperson: N. Van Mieghem
SHOW MORE

Summary

This session presents head-to-head comparisons of TAVI devices from recent randomized trials and registries. Highlights include three-year outcomes from the SMART trial, two-year data from the LANDMARK trial on contemporary valves, comparisons of intra- and supra-annular self-expanding valves, evaluations in large annuli, the ALLEGRA trial focusing on women, and health status analyses in young low-risk patients from the NOTION-2 study.

Presentations available when logged in:

  • Three-year outcomes of the SMART trial
  • Two-year outcomes of contemporary TAVI valves: LANDMARK, a randomised, non-inferiority trial
  • Outcomes after TAVI with latest-generation intra- and supra-annular self-expanding valves
  • TAVI in large annuli: Myval vs. Evolut R
  • ALL WOMEN: multicentre randomised clinical trial ALLEGRA vs. balloon-expandable valve in women
  • Health status after TAVI vs. surgical AVR in young low-risk patients with aortic stenosis: a NOTION-2 sub-analysis
Related Content
TAVI versus SAVR in aortic stenosis, is the debate still relevant in 2026? Structural and Valvular Interventions: EuroPCR 2026 highlights TAVI: LIVE Educational Case from Cleveland Clinic - London, UK
Recommended for you
Share your work with the Global Heart Team at #PCRLV PCR Rio Valves 2026 : Call for Submissions is now open PROTECT the head-to-head: Comparison of cerebral protection devices in TAVR